Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Mesothelioma, Malignant 1Lung Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Carboplatin 9pembrolizumab 7Pemetrexed 7Radiotherapy 5Magnetic Resonance Spectroscopy 5Specimen Handling 4Radiation 4Nivolumab 4Bevacizumab 4Platinum 3Paclitaxel 3Mastectomy, Segmental 3Cisplatin 3Biopsy 3fludarabine phosphate 2durvalumab 2capmatinib 2aldesleukin 2Taxes 2Radiotherapy, Conformal 2Radiosurgery 2Ipilimumab 2Interleukin-2 2Immunoglobulin G 2Disulfides 2Cyclophosphamide 2CTLA-4 Antigen 2Anterior Temporal Lobectomy 21,2-diaminocyclohexaneplatinum II citrate 2veliparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma of Lung × methoxyamine × 1 year × Clear all
NCT05198830 2026-05-27

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
42 enrolled
Thoracic

Adenocarcinoma of Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡